Journal: BMC Immunology

Article Title: Establishment and validation of a recurrent prediction model for glioma: extrinsic apoptotic molecules FADD and CASP8 are closely associated with glioma recurrence

doi: 10.1186/s12865-025-00746-z

Figure Lengend Snippet: The association between recurrent score and classical apoptotic genes. (A) The relationship between the 6 genes and recurrent score in CGGA and TCGA database . (B) PPI network of CASP3, CASP9, FADD, CASP7, CASP8, BCL2，and the 9-gene signature from the STRING. (C-D) The expression levels of the 6 apoptotic genes in low- and high-risk levels . (E-J) Correlation between recurrent score and expression levels of apoptotic genes. *P<0.05; ***P<0.001; ns, not significant

Article Snippet: Characterizing the differential expression patterns of CASP8 and FADD in gliomas and normal tissues will play a crucial role in the further development of targeted therapeutic strategies for gliomas Fig. 9 RNA and protein levels of CASP8 and FADD in normal tissues and tumors. (A-B) RNA expression of CASP8 and FADD in normal tissues from the NCBI database (https://www.ncbi.nlm.nih.gov/). (C-D) RNA expression of CASP8 and FADD in normal tissues from the Human Protein Atlas database (https://www.proteinatlas.org/). (E) Protein levels of CASP8 and FADD in normal brain tissues from The Human Protein Atlas database. (F) Protein levels of CASP8 and FADD in normal tissues from The Human Protein Atlas database. (G) Protein levels of CASP8 and FADD in tumors from The Human Protein Atlas database

Techniques: Expressing

Journal: BMC Immunology

Article Title: Establishment and validation of a recurrent prediction model for glioma: extrinsic apoptotic molecules FADD and CASP8 are closely associated with glioma recurrence

doi: 10.1186/s12865-025-00746-z

Figure Lengend Snippet: RNA and protein levels of CASP8 and FADD in normal tissues and tumors. (A-B) RNA expression of CASP8 and FADD in normal tissues from the NCBI database (https://www.ncbi.nlm.nih.gov/). (C-D) RNA expression of CASP8 and FADD in normal tissues from the Human Protein Atlas database (https://www.proteinatlas.org/). (E) Protein levels of CASP8 and FADD in normal brain tissues from The Human Protein Atlas database. (F) Protein levels of CASP8 and FADD in normal tissues from The Human Protein Atlas database. (G) Protein levels of CASP8 and FADD in tumors from The Human Protein Atlas database

Article Snippet: Characterizing the differential expression patterns of CASP8 and FADD in gliomas and normal tissues will play a crucial role in the further development of targeted therapeutic strategies for gliomas Fig. 9 RNA and protein levels of CASP8 and FADD in normal tissues and tumors. (A-B) RNA expression of CASP8 and FADD in normal tissues from the NCBI database (https://www.ncbi.nlm.nih.gov/). (C-D) RNA expression of CASP8 and FADD in normal tissues from the Human Protein Atlas database (https://www.proteinatlas.org/). (E) Protein levels of CASP8 and FADD in normal brain tissues from The Human Protein Atlas database. (F) Protein levels of CASP8 and FADD in normal tissues from The Human Protein Atlas database. (G) Protein levels of CASP8 and FADD in tumors from The Human Protein Atlas database

Techniques: RNA Expression

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing, Staining, RNA Sequencing

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Association of shared gene signatures and progressed cell death involving apoptosis and ferroptosis. (A) Expression levels of apoptosis-related genes in cardiomyocytes under a hyperglycemic environment (GSE 62203). (B) Expression levels of apoptosis-related genes in diabetic tubules (GSE 30122). (C) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected apoptosis-related genes in cardiomyocytes under a hyperglycemic environment (GSE 62203). (D) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected apoptosis-related genes in diabetic tubules (GSE 30122). (E) Expression levels of ferroptosis-related genes in diabetic cardiomyocytes (GSE 62203) and kidneys (GSE 30122). (F) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected ferroptosis-related genes in diabetic cardiomyocytes (GSE 62203) and kidneys (GSE 30122). (G) Expression levels of ferroptosis-related genes in the peripheral blood of patients with type II diabetes (GSE 23561) and glomeruli of diabetic nephropathy (GSE 96804). (H) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected ferroptosis-related genes in the peripheral blood of patients with type II diabetes (GSE 23561) and glomeruli of diabetic nephropathy (GSE 96804). The data has been normalized, and batch effects have been handled. A T-statistic test was employed to compare the expression levels of shared genes between the two groups. ∗ P < 0.05, ∗∗ P < 0.01 and ∗∗∗ P < 0.01 denotes statistical significance. DCM: diabetic cardiomyopathy; DT: diabetic tubuli; DNT: diabetic nephropathy tubuli; DNG: diabetic nephropathy glomeruli; DM: diabetes mellitus

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Clinical significance of shared genes in the Nephroseq database is illustrated through the following associations. (A) the relationship between PEA15 expression and glomerular filtration rate across all measured samples. (B) The correlation between PEA15 expression and serum creatinine levels in living donors. (C) The association of TFPI2 expression with glomerular filtration rate across all measured samples, and (D) The relationship between TFPI2 expression and serum creatinine levels in samples from patients with diabetic nephropathy.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing, Filtration

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Molecular docking of candidate compounds and shared genes, including transcription factor s. (A) Affinities of candidate compounds with RUNX2 (a transcription factor for PEA15), PEA15, and TFPI2. (B) Affinities of candidate compounds with transcription factors (HBA1, HBA2, and HBB) corresponding to the three hemoglobin subunits.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: